Lunovus’s Visual Advantage AREDS II formula is based on the AREDS II study.
The AREDS formula, which was published in 2001, resulted in a 25 percent
reduction in the progression of AMD in the original AREDS study and this was
also shown to be true in the AREDS II study with an even better result. The
use of specific dosages of lutein and zeaxanthin in the AREDS II study showed
further reduction of the progression of AMD even better than the first AREDS
study, which did not have lutein or zeaxanthin. In the AREDS II study the beta
carotene (Vitamin A) was found to decrease the absorption and the efficacy of
lutein and zeaxanthin. Therefore, Beta carotene should not be used and lutein
and zeaxanthin should take its place resulting in an even better reduction of
the progression of AMD. The AREDS II study showed that a lower dose of zinc at
25mg was just as efficient as a dose of zinc at 80mg. Therefore we have
included the lower dose zinc in our formula which will also help to offset the
stomach irritation many patients have felt while taking an eye supplement.
Lunovus’s Visual Advantage is specially formulated in the United States by an
FDA inspected and GMP compliant facility. We utilize today’s latest medical
technology to engineer the finest pharmaceutical grade supplements available
to the consumer. We adhere to rigorous testing to ensure every raw ingredient
that is used to make each supplement meets the highest standard. We know the
importance of choosing the right manufacturer when it comes to your vision and
take great pride in every product we manufacture.